{"filings":[{"id":470237,"accession_number":"0000874716-26-000110","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2026-05-15T20:00:10+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"IDEXX shareholders approve board declassification and 25% special meeting right","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board declassification approved; all directors to be elected annually starting at 2029 annual meeting.","Shareholders owning 25% of stock continuously for at least 1 year can now call a special meeting.","Bylaws amended effective May 13, 2026; certificate of amendment filed with Delaware.","All three Class II director nominees elected: Junius, Kingsley, Vandebroek with >60M votes each.","Shareholder proposal for special meeting right failed with 28M for vs 40M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99324,"accession_number":"0001104659-26-055203","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IDEXX Q1 beats: rev $1.14B (+14%), EPS $3.47 (+17%); raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $1,141M (+14% as reported, +11% organic); EPS $3.47 (+17% as reported, +15% comparable).","CAG Diagnostics recurring revenue +14% as reported, +11% organic; premium instrument installed base +12%.","FY2026 revenue guidance raised $42M at midpoint to $4,675-$4,760M; EPS guidance to $14.45-$14.90.","Organic revenue growth guidance raised to 7.7%-9.7% from 7.0%-9.0%; operating margin expansion 50-90 bps.","CEO Jay Mazelsky to transition; Mike Erickson will continue as a key leader (mentioned in earnings release)."],"consensus_eps_estimate":null,"consensus_eps_actual":3.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":1140820000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115256,"accession_number":"0001104659-26-034906","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"IDEXX EVP Nimrata Hunt to depart Apr 13; position eliminated, advisory role until Jul 13","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Nimrata Hunt, EVP Global Strategy & Commercial, steps down effective Apr 13, 2026; position eliminated.","Advisory role from Apr 13 to Jul 13, 2026; per diem pay based on current base salary.","Separation benefits: $1.23M salary continuation (104 weeks), $984K bonus (2 years), plus COBRA; ~$2.29M total.","All unvested equity awards forfeited as of Jul 13; vested options remain exercisable per award terms.","No successor named; restructuring of global strategy & commercial function."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115255,"accession_number":"0000874716-26-000007","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2026-02-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director M. Anne Szostak to retire from IDEXX Board effective May 12, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Szostak notified Board on Feb 13, 2026; retirement effective after 2026 Annual Meeting.","Szostak has served since 2012; departure not due to any disagreement with Company or Board.","Board reduces Class III size upon her retirement; overall Board unchanged by prior appointment of Michael G. Erickson as Class II member."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115254,"accession_number":"0001104659-26-008904","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2026-02-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IDEXX Q4 revenue $1.09B (+14% YoY), EPS $3.08 (+18%); guides FY26 rev $4.63B-$4.72B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $1,091M (+14% as reported, +12% organic); EPS $3.08 (+18% as reported, +17% comparable).","Full year 2025 revenue $4,304M (+10%); EPS $13.08 (+23% reported, +14% comparable).","CAG Diagnostics recurring revenue grew 12% reported; record >1,900 IDEXX inVue Dx placements in Q4.","FY26 guidance: rev $4,632M-$4,720M (7.6%-9.6% reported growth); EPS $14.29-$14.80 (9%-13% growth).","Operating margin expanded 150 bps reported in Q4 to 28.9%; gross margin 60.3%, up 50 bps."],"consensus_eps_estimate":null,"consensus_eps_actual":13.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":4303702000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115253,"accession_number":"0001104659-26-003103","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2026-01-13T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"IDEXX CEO succession: Mike Erickson to become President and CEO on May 12, 2026; Mazelsky to Executive Chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jay Mazelsky steps down as CEO effective May 12, 2026, transitions to Executive Chair; will retire from board in May 2027.","Michael Erickson, PhD (EVP & GM Global Point of Care), promoted to President and CEO, joining the board.","Erickson's compensation: $1M base salary, 120% target bonus, FY2026 equity target at least $7.8M (50% options, 50% PSUs).","Mazelsky's Executive Chair compensation: $1.15M base, blended bonus target, $8.275M RSU grant in Feb 2026.","Lawrence Kingsley, currently Non-Executive Chair, becomes independent Lead Director after transition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131676,"accession_number":"0001104659-25-111278","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"IDEXX amends credit facility: extends revolver to 2030, adds $250M term loan due 2028","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amendment extends $1.0B revolver maturity to 5 years from Nov 12, 2025; adds $250M term loan due 3 years from closing.","IDEXX Holdings II GmbH (Switzerland) added as new borrower under the credit agreement.","Departing lenders repaid; new lenders join; interest rates tied to consolidated leverage ratio.","Incremental capacity of up to $250M retained for future revolving or term loans."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131675,"accession_number":"0001104659-25-105185","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IDEXX Q3 revenue $1.1B (+13%), EPS $3.40 (+21%); raises FY2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1,105M (+13% reported, +12% organic); CAG Diagnostics recurring revenue +11% reported, +10% organic.","EPS $3.40 (+21% reported, +15% comparable); operating margin 32.1%, +100 bps reported.","Raises FY2025 revenue guidance to $4,270-$4,300M (midpoint +$43M) and EPS guidance to $12.81-$13.01 (midpoint +$0.33).","Over 1,700 IDEXX inVue Dx placements in Q3; strong capital instrument revenue growth of 74% reported.","Updated FY2025 organic revenue growth outlook 8.8%-9.5%; comparable margin expansion guidance raised to 80-100 bps."],"consensus_eps_estimate":null,"consensus_eps_actual":9.99,"consensus_revenue_estimate":null,"consensus_revenue_actual":3213123000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131674,"accession_number":"0001104659-25-097319","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2025-10-07T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"IDEXX elects Karen Peacock as independent Class I director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Karen Peacock elected independent Class I director, effective October 6, 2025, filling a newly created seat.","She will serve on Compensation and Talent Committee and Finance Committee; standard director compensation applies prorated.","Peacock is former CEO of Intercom, ex-SVP at Intuit, and currently lead independent director at Dropbox.","Board expanded from ten to eleven directors; she will stand for election at 2027 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148241,"accession_number":"0001104659-25-073304","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IDEXX Q2 EPS $3.63 (+49% reported); raises FY2025 revenue and EPS guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $1,109M (+11% reported, +9% organic); CAG Diagnostics recurring revenue +9% reported, +7% organic.","Record quarterly instrument placements including nearly 2,400 IDEXX inVue Dx units.","FY2025 revenue guidance raised to $4,205M-$4,280M (prior $4,095M-$4,210M); organic growth outlook 7.0%-9.0%.","FY2025 EPS guidance raised to $12.40-$12.76 (prior $11.93-$12.43); reported growth 16%-20%.","Operating margin guidance improved to 31.3%-31.6%; comparable expansion 50-80 bps."],"consensus_eps_estimate":null,"consensus_eps_actual":6.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":2107884000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148240,"accession_number":"0001104659-25-066840","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2025-07-10T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"IDEXX elects former State Street CEO Joseph L. Hooley to Board; board expands to 10","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Joseph L. (Jay) Hooley elected as independent Class III Director effective July 10, 2025.","Hooley served as Chair and CEO of State Street Corporation (2011-2019 / 2010-2018).","Board expanded from 9 to 10 directors; Hooley appointed to Audit and Governance & Corporate Responsibility Committees.","Hooley also serves on boards of Exxon Mobil Corporation and Aptiv PLC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167010,"accession_number":"0000874716-25-000085","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2025-05-09T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"IDEXX shareholders approve charter amendments removing supermajority, officer exculpation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed Certificate of Elimination for Series A Preferred Stock; preferred shares revert to undesignated status.","Shareholders approved removal of supermajority voting provisions from the certificate of incorporation.","Shareholders approved amendment allowing officer exculpation under Delaware law.","Board amended bylaws to include exclusive forum provision for Delaware courts and update procedural rules.","Elected Stuart Essig, Jonathan Mazelsky, M. Anne Szostak as Class III directors for terms until 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167009,"accession_number":"0001104659-25-042955","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IDEXX Q1 EPS $2.96 (+5%), rev $998M (+4%); raises FY25 revenue & EPS outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $998M (+4% reported, +5% organic); EPS $2.96 (+5%, +7% comparable).","CAG Diagnostics recurring revenue +3% reported, +4.5% organic; VetLab consumables organic +10%.","Launched IDEXX Cancer Dx for early canine lymphoma detection in North American reference labs.","FY25 revenue guidance raised to $4,095M-$4,210M; EPS guidance raised to $11.93-$12.43 ($0.19 increase).","FY25 organic revenue growth outlook maintained at 6%-9%; comparable EPS growth maintained at 8%-12%."],"consensus_eps_estimate":null,"consensus_eps_actual":2.96,"consensus_revenue_estimate":null,"consensus_revenue_actual":998427000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184386,"accession_number":"0000874716-25-000011","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2025-02-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"IDEXX director Asha Collins resigns from Board, effective immediately","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Asha Collins resigned from the Board of Directors on February 13, 2025.","Resignation was not due to any disagreement with the Company on operations, policies, or practices.","Board size reduced from ten to nine directors following the resignation.","Company and Board thanked Dr. Collins for her service."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184385,"accession_number":"0001104659-25-008331","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2025-02-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IDEXX Q4 revenue $954M (+6% YoY), EPS $2.62; guides 2025 rev $4.06-$4.17B, EPS $11.74-$12.24","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $954M (+6% reported and organic); CAG Diagnostics recurring revenue +7% organic.","Q4 EPS $2.62 (+13% as reported, +10% comparable); full year EPS $10.67 (+12% comparable).","2025 revenue guidance $4.055-$4.170B (+4-7% reported, +6-9% organic); EPS $11.74-$12.24 (+10-15% reported).","Expects ~$1.5B in share repurchases in 2025 (~4% of market cap), subject to market conditions.","2024 full year revenue $3.898B (+6% as reported and organic); targets 200-250 bps operating margin improvement in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":10.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":3897504000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200987,"accession_number":"0000874716-24-000150","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2024-12-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"IDEXX Laboratories adopts nonqualified deferred compensation plan for select management and highly compensated employees","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Participants may defer 5–50% of base salary, 5–100% of annual bonus, and 5–100% of stock units.","Cash deferrals fully vested; stock unit deferrals vest per award agreement; discretionary company contributions may vest on change in control, death, disability, or retirement.","Company currently has no intention to make discretionary contributions; distributions occur upon separation, specified date, death, or unforeseeable emergency.","Stock unit deferrals settled in shares; cash deferrals deemed invested in participant-chosen options; all accounts are unfunded unsecured promises.","Plan effective Dec 6, 2024; administered by Compensation and Talent Committee and Employee Plans Administrative Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200986,"accession_number":"0000874716-24-000148","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2024-12-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"IDEXX boosts share repurchase authorization by 5M shares, adds to 1.3M remaining","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized repurchase of up to five million additional shares of common stock.","New authorization is in addition to the 1.3 million shares remaining under prior approval as of Dec 3, 2024.","Repurchases may be made in open market or negotiated transactions; program has no expiration date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200985,"accession_number":"0001104659-24-121326","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2024-11-21T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"IDEXX CFO Brian McKeon to retire June 2025; Andrew Emerson named successor effective March 1, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["McKeon will retire June 1, 2025; will step down as CFO March 1, 2025 and serve as Special Advisor until retirement.","Andrew Emerson appointed EVP, CFO and Treasurer effective March 1, 2025; previously SVP Corporate and CAG Finance.","Emerson's compensation: base salary $550K, target bonus 75% of salary, eligible for annual equity grants, change-in-control benefits.","McKeon oversaw significant growth; Emerson has nine years at IDEXX leading CAG finance and corporate finance since 2020.","Company reaffirmed full-year 2024 guidance as provided on October 31, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200984,"accession_number":"0001104659-24-116365","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Board member Jonathan W. Ayers resigns from IDEXX Board effective Nov 8, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ayers resigned from Board and Finance Committee effective November 8, 2024.","Ayers served as Chairman, President and CEO from 2002-2019; non-employee director since 2019.","Resignation not due to any disagreement with company's operations, policies, or practices.","Board size reduced from 11 to 10 directors; no replacement named."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200983,"accession_number":"0000874716-24-000142","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"IDEXX extends Ortho-Clinical Diagnostics supply agreement to 2044, revises pricing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IDEXX entered U.S. and European supply agreement amendments with Ortho-Clinical Diagnostics for dry slides used in veterinary chemistry analyzers.","Expiration dates of both agreements extended to end of 2044.","Pricing arrangements modified, including volume tiers and pricing over contract terms.","Amendments effective as of October 31, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200982,"accession_number":"0001104659-24-112826","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IDEXX Q3 EPS $2.80, revenue $976M; cuts FY24 revenue guidance citing macro headwinds","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $976M (+7% reported, +6% organic); EPS $2.80 (+11% reported, +12% comparable).","CAG Diagnostics recurring revenue +7% reported and organic; global premium instrument installed base +10% YoY.","FY24 revenue guidance cut $38M at midpoint to $3,865M-$3,890M; organic growth now 5.3%-6.0% (prior 6.2%-7.8%).","EPS guidance narrowed to $10.37-$10.53, midpoint unchanged; $0.56 negative impact from litigation accrual.","Water revenue +13%; LPD -3%. Gross margin 61.1% (+120 bps). Operating margin 31.2% (+110 bps)."],"consensus_eps_estimate":null,"consensus_eps_actual":8.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":2943216000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200981,"accession_number":"0001104659-24-112975","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K/A","filed_at":"2024-10-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IDEXX corrects FY24 comparable margin expansion to 30-60 bps (from 70-100 bps); Q3 EPS $2.80","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Corrected 2024 comparable operating profit margin expansion to 30-60 bps from 70-100 bps (error in prior release).","Q3 revenue $976M (+7% reported, +6% organic); CAG Diagnostics recurring revenue +7%.","Q3 diluted EPS $2.80, +11% as reported, +12% comparable basis; operating margin 31.2%.","Updated FY24 revenue guidance to $3.865B-$3.890B (~1% lower at midpoint); EPS narrowed to $10.37-$10.53.","FY24 organic revenue growth now 5.3%-6.0% (prior 6.2%-7.8%) due to softer U.S. clinic visit trends."],"consensus_eps_estimate":null,"consensus_eps_actual":8.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":2943216000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216997,"accession_number":"0001104659-24-086074","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IDEXX Q2 rev +6% to $1,004M; EPS $2.44; cuts FY guidance on litigation charge","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1,004M, +6% reported (+7% organic); CAG Diagnostics recurring +6% reported (+7% organic).","EPS $2.44, down 9% reported; comparable +15% excluding $0.56/share discrete litigation accrual.","Record Q2 premium instrument placements; global premium instrument installed base grew 11% YoY.","FY2024 guidance updated: revenue $3,885M-$3,945M (6.2-7.8% organic); EPS $10.31-$10.59, down $0.56 at midpoint.","$62M discrete litigation expense accrual hit operating margin by ~610 bps and EPS by $0.56."],"consensus_eps_estimate":null,"consensus_eps_actual":5.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":1967673000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236749,"accession_number":"0000874716-24-000107","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2024-05-10T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"IDEXX enters $25K/month consulting pact with retired EVP; all annual meeting proposals pass","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Retired EVP James Polewaczyk to provide coaching; $25,000/month for one-year term starting May 7, 2024.","All four Class I director nominees elected: Britt, Claflin, Collins, Samad with >64M votes each.","Advisory vote on executive compensation approved: 64.3M for, 4.4M against.","Shareholder proposal for simple majority vote passed: 61.4M for, 6.4M against.","Ratification of PwC as auditor approved: 70.5M for, 3.9M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236748,"accession_number":"0001104659-24-055201","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2024-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IDEXX Q1 revenue $964M (+7%), EPS $2.81; cuts 2024 revenue/EPS guidance on FX and visit slowdown","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $964M (+7% as reported and organic); EPS $2.81 (+10% reported, +9% comparable).","CAG Diagnostics recurring revenue grew 7% as reported and organic; global premium instrument installed base up 11% YoY.","FY2024 revenue guidance lowered to $3,895M-$3,965M (prior $3,930M-$4,040M); EPS guidance lowered to $10.82-$11.20.","Guidance cut reflects ~$35M FX headwind and reduction of 1% from high end of organic growth range due to US clinical visit moderation.","Gross margin improved 120bps to 61.5%; operating margin contracted 10bps to 31.0% due to lapping a Q1 2023 customer contract resolution payment."],"consensus_eps_estimate":null,"consensus_eps_actual":2.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":964095000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}